GLPG Galapagos NV Stock Quote

GLPG [NASD]

Index	-	P/E	-	EPS (ttm)	-4.49	Insider Own	-	Shs Outstand	65.52M	Perf Week	4.61%
Market Cap	3.43B	Forward P/E	-	EPS next Y	-3.92	Insider Trans	-	Shs Float	43.18M	Perf Month	-4.43%
Income	-	PEG	-	EPS next Q	-1.41	Inst Own	9.99%	Short Float	1.00%	Perf Quarter	-13.67%
Sales	590.28M	P/S	5.82	EPS this Y	28.80%	Inst Trans	-	Short Ratio	1.60	Perf Half Y	-36.97%
Book/sh	41.24	P/B	1.27	EPS next Y	2.50%	ROA	-	Target Price	80.46	Perf Year	-59.82%
Cash/sh	-	P/C	-	EPS next 5Y	0.71%	ROE	-	52W Range	48.66 - 133.91	Perf YTD	-47.06%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-60.87%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	7.69%	ATR	1.46
Employees	1397	Current Ratio	-	Sales Q/Q	34.70%	Oper. Margin	-	RSI (14)	46.13	Volatility	2.27% 2.08%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.35	Prev Close	51.65
Shortable	Yes	LT Debt/Eq	-	Earnings	Aug 05 AMC	Payout	-	Avg Volume	271.49K	Price	52.40
Recom	2.80	SMA20	0.24%	SMA50	-5.85%	SMA200	-29.39%	Volume	94,603	Change	1.45%

Aug-19-21

Downgrade

Barclays

Overweight → Equal Weight

Aug-06-21

Downgrade

Deutsche Bank

Buy → Hold

Apr-20-21

Initiated

Deutsche Bank

Buy

Apr-14-21

Upgrade

Barclays

Equal Weight → Overweight

Feb-23-21

Upgrade

BofA Securities

Underperform → Neutral

$93 → $94

Feb-19-21

Upgrade

Raymond James

Mkt Perform → Outperform

Feb-11-21

Downgrade

Citigroup

Buy → Neutral

Jan-19-21

Upgrade

Morgan Stanley

Equal-Weight → Overweight

$159 → $129

Nov-19-20

Initiated

Maxim Group

Buy

$170

Oct-21-20

Downgrade

Goldman

Neutral → Sell

Aug-25-20

Downgrade

Jefferies

Buy → Hold

Aug-24-20

Downgrade

H.C. Wainwright

Buy → Neutral

$270 → $123

Aug-19-20

Upgrade

Citigroup

Neutral → Buy

Aug-19-20

Downgrade

Barclays

Overweight → Equal Weight

Jul-10-20

Downgrade

Stifel

Buy → Hold

$298 → $193

Mar-30-20

Upgrade

Jefferies

Hold → Buy

$232

Mar-18-20

Upgrade

RBC Capital Mkts

Underperform → Sector Perform

$175 → $157

Feb-25-20

Downgrade

Cantor Fitzgerald

Overweight → Neutral

Feb-24-20

Downgrade

BofA/Merrill

Neutral → Underperform

Feb-20-20

Downgrade

RBC Capital Mkts

Sector Perform → Underperform

$175

Oct-05-21 01:08PM	Galapagos (GLPG) Concludes Enrollment in Crohn's Disease Study Zacks
09:04AM	Galapagos' Filgotinib Shows Clinical Benefit In Ulcerative Colitis Non-Responding Patients Benzinga
Oct-04-21 04:01PM	Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congress GlobeNewswire
07:08AM	Galapagos Assumes Responsibility Of Late-Stage Filgotinib Trial In Crohn's Disease Benzinga
01:01AM	Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohns Disease GlobeNewswire
Sep-20-21 04:01PM	Galapagos increases share capital through subscription right exercises GlobeNewswire
Sep-17-21 07:15AM	GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS GlobeNewswire
Aug-31-21 09:03AM	Galapagos' Long-Serving CEO Onno Van De Stolpe To Exit After R&D Setbacks Benzinga +7.00%
Aug-30-21 04:01PM	Galapagos announces planned retirement of CEO GlobeNewswire
Aug-07-21 01:00AM	Galapagos NV (GLPG) Q2 2021 Earnings Call Transcript Motley Fool
Aug-05-21 04:01PM	Galapagos reports H1 financial results with refocused pipeline and operational progress GlobeNewswire
Jul-21-21 05:29AM	Hedge Funds Are Buying Galapagos NV (GLPG) Insider Monkey
Jul-15-21 04:20PM	Here's Why Galapagos Stock Is Falling Today Motley Fool -13.02%
10:36AM	Galapagos (GLPG) Falls on Inflammatory Study Data Readout Zacks
05:49AM	Galapagos' Another Psoriasis Candidate Shows Efficacy, Safety Profile In Mid-Stage Study Benzinga
05:45AM	Galapagos Shares Drop As SIK Inhibitor Fails To Show Positive Outcomes In Ulcerative Colitis, Rheumatoid Arthritis Patients Benzinga
Jul-14-21 04:01PM	Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study GlobeNewswire
04:01PM	Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation GlobeNewswire
Jul-10-21 05:10AM	Galapagos announces new data supporting rapid symptom improvement and sustained steroid-free remission with filgotinib in patients with Ulcerative Colitis GlobeNewswire
Jun-22-21 04:01PM	Galapagos announces departure of CSO Piet Wigerinck later this year GlobeNewswire
Jun-07-21 04:01PM	Galapagos increases share capital through subscription right exercises GlobeNewswire
Jun-04-21 01:01AM	SELECTION study on filgotinib in ulcerative colitis published in The Lancet GlobeNewswire
May-27-21 04:01PM	Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress GlobeNewswire
May-18-21 04:01PM	Galapagos announces first patient enrolled in FILOSOPHY study to advance understanding of Jyseleca (filgotinib) effectiveness and safety in a real-world setting GlobeNewswire
May-07-21 08:00PM	Galapagos NV (GLPG) Q1 2021 Earnings Call Transcript Motley Fool
May-06-21 04:01PM	Galapagos refocuses pipeline and rightsizes operations GlobeNewswire
May-04-21 04:01PM	Transparency notification received from The Capital Group GlobeNewswire
Apr-30-21 04:01PM	Galapagos creates new subscription right plans GlobeNewswire
Apr-23-21 12:01AM	Gilead Sciences submits new drug application in Japan for filgotinib for the treatment of ulcerative colitis with an inadequate response to conventional therapies GlobeNewswire
Apr-08-21 04:01PM	Extension of lock-up period in Gilead-Galapagos collaboration agreement GlobeNewswire
Mar-25-21 04:01PM	Publication of the annual report and invitation to the ordinary shareholders meeting GlobeNewswire
Mar-24-21 04:01PM	Galapagos appoints Bart Filius as President and Chief Operating Officer GlobeNewswire
Mar-19-21 05:01PM	Galapagos increases share capital through subscription right exercises GlobeNewswire
Mar-16-21 09:10PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG ACCESSWIRE
Mar-14-21 10:38PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG Newsfile
Mar-12-21 04:55AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG PR Newswire
Mar-10-21 09:45PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG ACCESSWIRE
Mar-07-21 01:13PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG Newsfile
Mar-04-21 08:12AM	The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company Benzinga
01:49AM	GALAPAGOS REPORTS PRIMARY ENDPOINT FOR THE ONGOING FILGOTINIB MANTA AND MANTA-RAy SAFETY STUDIES GlobeNewswire
Mar-03-21 04:15PM	Transparency notification received from The Capital Group GlobeNewswire
03:20AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG PR Newswire
Feb-23-21 06:55AM	Is Galapagos Stock a Bad-News Buy Right Now? Motley Fool
Feb-22-21 02:20PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG Newsfile
07:21AM	Galapagos: Upside Optionality Remains Despite Clinical Trial Failure TipRanks
Feb-20-21 06:15PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG ACCESSWIRE
Feb-19-21 06:30PM	Galapagos NV (GLPG) Q4 2020 Earnings Call Transcript Motley Fool
12:15PM	Galapagos NV to Host Earnings Call ACCESSWIRE
01:05AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG PR Newswire
Feb-18-21 04:01PM	Pipeline and capital for growth GlobeNewswire
Feb-15-21 10:00PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG Newsfile
Feb-13-21 03:00PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG ACCESSWIRE
Feb-11-21 03:28PM	Gilead (GILD) & Galapagos Discontinue Development of IPF Drug Zacks
02:10PM	Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Galapagos NV (GLPG) Investigation ACCESSWIRE
11:18AM	Stocks That Hit 52-Week Lows On Thursday Benzinga
08:25AM	Gilead, Galapagos drug fails in Phase 3 clinical study MarketWatch
Feb-10-21 02:52PM	Gilead Sciences and Galapagos Shutter Their Pulmonary Fibrosis Program Motley Fool -17.76%
11:10AM	Galapagos, Gilead Sciences Pull Plug On Ziritaxestat Clinical Trials Benzinga
09:00AM	Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF Business Wire
Feb-09-21 04:01PM	The Capital Group holds 10.03% of Galapagos shares GlobeNewswire
Jan-21-21 02:08AM	NICE recommends Jyseleca® (filgotinib) on NHS in landmark decision for rheumatoid arthritis GlobeNewswire
Jan-12-21 11:54AM	Prime Minister announces new Commissioner of Nunavut CNW Group
Jan-11-21 04:01PM	Gilead holds 25.54% of Galapagos shares GlobeNewswire
Jan-06-21 09:30AM	Galapagos to present at 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-05-21 12:15PM	Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Galapagos NV (GLPG) Investigation ACCESSWIRE
Jan-04-21 04:05PM	Selvita completes acquisition of Fidelta from Galapagos PR Newswire
04:01PM	Selvita completes acquisition of Fidelta from Galapagos GlobeNewswire
Dec-29-20 11:50PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG ACCESSWIRE
Dec-28-20 07:00AM	Is Gilead Stock A Buy As The Company Expands Through Buyouts? Investor's Business Daily
Dec-26-20 03:24PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG Newsfile
Dec-23-20 09:20PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG ACCESSWIRE
12:00PM	Galapagos CEO makes donation of 10 million in the form of personal shares to African Parks GlobeNewswire
Dec-18-20 11:00AM	Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Galapagos NV (GLPG) Investigation ACCESSWIRE
Dec-17-20 09:35AM	Company News for Dec 17, 2020 Zacks
Dec-16-20 09:59PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG Newsfile -18.78%
04:33PM	Galapagos Stock Crumbles After Its Gilead Arthritis Deal Falls Apart Investor's Business Daily
01:42PM	Gilead (GILD) to Not Seek FDA Approval of RA Drug, Amends Deal Zacks
01:37PM	Biotech Stock Roundup: ALXN Up on Acquisition News, PFE-BNTX Get EUA for Vaccine & More Zacks
07:15AM	The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal Benzinga
Dec-15-20 04:15PM	Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib) Business Wire
04:15PM	Gilead and Galapagos announce New Commercialization and Development Agreement for Jyseleca® (filgotinib) GlobeNewswire
Dec-12-20 06:50PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG GlobeNewswire
07:20AM	3 Stocks That Are Giving Their Investors Coal in Their Stockings Motley Fool
Dec-11-20 12:44PM	Is GLPG A Good Stock To Buy Now? Insider Monkey
Dec-10-20 05:17PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG PR Newswire
06:56AM	Investors: How Would You Grade Gilead Sciences' CEO? Motley Fool
Dec-04-20 04:01PM	Galapagos increases share capital through subscription right exercises GlobeNewswire
Dec-01-20 04:01PM	Galapagos announces first dosing in MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease GlobeNewswire
08:08AM	The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit Benzinga
Nov-30-20 04:01PM	Galapagos reports positive topline results with GLPG1205 in IPF patients in PINTA Proof-of-Concept trial GlobeNewswire
Nov-28-20 06:45AM	Gilead's New CEO Is Going All-In on Acquisitions Motley Fool
Nov-23-20 04:15PM	Selvita to acquire Fidelta from Galapagos PR Newswire
Nov-09-20 04:01PM	First patient dosed with GLPG3667 in psoriasis patient Phase 1b trial GlobeNewswire
Nov-05-20 04:15PM	OncoArendi and Galapagos enter into exclusive collaboration on chitinase inhibitors in fibrosis GlobeNewswire
04:01PM	Galapagos reports Q3 2020 results GlobeNewswire
Nov-02-20 04:01PM	European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Ulcerative Colitis Business Wire
Oct-28-20 06:06PM	Gilead Sciences Benefits From Its Initial Quarter of Remdesivir Sales Barrons.com -5.80%
Oct-27-20 11:21AM	Galapagos R&D Roundtable showcases Toledo program GlobeNewswire
Oct-23-20 02:05PM	7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio InvestorPlace
Oct-22-20 04:22PM	Gileads Sales Will Slip Even With Remdesivir Barrons.com

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjogren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.A r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience